BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Dana-Farber Cancer Institute - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://ds.dfci.harvard.edu
X-WR-CALDESC:Events for Dana-Farber Cancer Institute
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210209T130000
DTEND;TZID=America/New_York:20210209T140000
DTSTAMP:20260423T013858
CREATED:20200921T175912Z
LAST-MODIFIED:20210511T181321Z
UID:2129-1612875600-1612879200@ds.dfci.harvard.edu
SUMMARY:Frontiers in Biostatistics: Group Sequential Design Assuming Delayed Benefit
DESCRIPTION:February 9\, 2021\n1:00PM ET \nKeaven Anderson\, PhD\nScientific AVP\, Methodology Research\, Biostatistics at Merck \nGroup Sequential Design Assuming Delayed Benefit \nAbstract: We consider an asymptotic approach to design of group sequential trials with a potentially delayed effects. Logrank\, weighted logrank tests and combination tests are of primary interest\, but we also consider restricted mean survival. The asymptotic approach allows both quick derivation of study design properties that are also easily verified using simulation. We rely heavily on work done by Tsiatis\, 1981 published while he was at the HSPH. The impact of a potential delay in treatment effect on timing of analyses\, study boundaries and sample size are demonstrated. The value of a robust design that is well powered under a variety of assumptions is emphasized. Open source software is provided for implementation. Given the current regulatory climate\, logrank testing may still be preferred for these trials\, but we hope that efficiencies and Type I error control associated with alternatives may make other options more acceptable for future consideration. \nYouTube Link: https://www.youtube.com/watch?v=DhwZOX5uMKU
URL:https://ds.dfci.harvard.edu/event/frontiers-in-biostatistics-keaven-anderson/
CATEGORIES:Seminar
ATTACH;FMTTYPE=image/jpeg:https://ds.dfci.harvard.edu/wp-content/uploads/2020/09/anderson1.jpg
END:VEVENT
END:VCALENDAR